Paul Cayer's Email & Phone

Paul Cayer - Chief Business Officer. Mr. Cayer has more than 25 years of experience in the pharmaceutical, medical device, and healthcare technology field. Before joining Otonomy, Mr. Cayer served as Senior Vice President, Corporate Development for Verus Pharmaceuticals, a venture-backed specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. Verus raised over $150M from top-tier venture and private capital groups to build a national field sales force and fund the development of innovative products for this underserved patient segment. In support of this mission, Mr. Cayer was responsible for numerous corporate partnering and new product assessment projects. During his tenure, Verus completed three out-licensing/divestiture transactions with total potential consideration exceeding $350M. Mr. Cayer joined Verus from Targeted Molecules Corporation where he served as the Chief Financial Officer and Senior Vice President, Business Development. TMC was a venture-backed biopharmaceutical company formed to exploit a proprietary drug discovery platform developed at The Burnham Institute. As the company's only business executive, responsibilities encompassed all facets of daily operations including management of financial, legal and administrative matters, strategic planning, fund-raising, budgeting and forecasting, corporate promotion, and partnering. TMC was acquired in 2005. Previously, Mr. Cayer worked in various commercial roles at Gensia Pharmaceuticals, product development marketing at Acuson, business planning and development with Castle & Cooke, and management consulting with Booz-Allen & Hamilton. Mr. Cayer received his BA in Biomechanical Engineering and MBA from Harvard University.